Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee
- 131 Downloads
Triamcinolone acetonide extended-release (ER) 32 mg (Zilretta®) is approved in the USA for the management of osteoarthritis (OA) pain of the knee and is administered as a single, 5 mL intra-articular (IA) injection. Although the therapeutic effects from IA corticosteroids are typically short-lived, triamcinolone acetonide ER is formulated in poly (lactic-co-glycolic acid) (PLGA) microspheres that slowly release triamcinolone acetonide in the synovium, enabling their prolonged presence in the joint. This reduces systemic exposure and lessens corticosteroid-related systemic adverse reactions, such as blood glucose elevations. In a 24-week, randomized, phase III clinical trial, triamcinolone acetonide ER 32 mg significantly improved mean average daily pain intensity in patients with knee OA relative to placebo, and pain, stiffness and physical function (according to WOMAC criteria) relative to placebo and triamcinolone acetonide crystalline suspension (CS). Triamcinolone acetonide ER was generally well tolerated, with a tolerability profile similar to that of triamcinolone acetonide CS and placebo. Findings from a single-arm phase IIIb study indicated that a repeat administration of triamcinolone acetonide ER may be similarly efficacious to an initial injection without having deleterious effects on cartilage or other aspects of joint structure. Thus, triamcinolone acetonide ER expands the treatment options available for the management of OA pain of the knee.
During the peer review process, the manufacturer of triamcinolone acetonide ER was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
Julia Paik, Sean Duggan and Susan Keam are salaried employees of Adis/Springer and declare no relevant conflicts of interest.
- 2.Osteoarthritis Research Society International. Osteoarthritis: a serious disease, a white paper submitted to the U.S. Food and Drug Administration. 2016. https://www.oarsi.org/. Accessed 22 Feb 2019.
- 6.Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995;38(11):1541–6.Google Scholar
- 7.Juni P, Hari R, Rutjes AW, et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev. 2015(10):CD005328.Google Scholar
- 11.Flexion Therapeutics Inc. ZILRETTA (triamcinolone acetonide extended-release injectable suspension): US prescribing information. 2017. https://www.accessdata.fda.gov/. Accessed 22 Feb 2019.
- 12.US Center for Drug Evaluation and Research. Non-clinical review(s) (Zilretta). 2017. https://www.accessdata.fda.gov/. Accessed 22 Feb 2019.
- 14.Flexion Therapeutics Inc. ZILRETTA® (triamcinolone acetonide extended-release injectable suspension). 2019. https://flexiontherapeutics.com/our-product/. Accessed 22 Feb 2019.
- 16.Jackson D, Cotton L, Turkington M, et al. Physical and chemical compatibility of extended-release triamcinolone acetonide (TA-ER) with common local anesthetics. Adv Ther. 2019. https://doi.org/10.1007/s12325-019-0878-2.
- 18.US Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review (Zilretta). 2017. https://www.accessdata.fda.gov/. Accessed 22 Feb 2019.
- 19.Wernecke C, Braun HJ, Dragoo JL. The effect of intra-articular corticosteroids on articular cartilage: a systematic review. Orthop J Sports Med. 2015;3(5):2325967115581163.Google Scholar
- 21.Williamson TL, Walz A, Garlick D, et al. Systemic and local effects following intra-articular injection of FX006, an extended release, PLGA microsphere formulation of triamcinolone acetonide: results from two nonclinical toxicity studies in dogs (abstract no. 713). Osteoarthr Cartil. 2017;25(Suppl. 1):S431–S2.Google Scholar
- 24.Kraus VB, Conaghan PG, Aazami HA, et al. Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). Osteoarthr Cartil. 2018;26(1):34–42.CrossRefGoogle Scholar
- 25.Collegium Pharmaceutical Inc. AllerNaze (triamcinolone acetonide nasal spray): US prescribing information. 2009. https://www.accessdata.fda.gov/. Accessed 22 Feb 2019.
- 28.Conaghan PG, Hunter DJ, Cohen SB, et al. Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study. J Bone Jt Surg Am. 2018;100(8):666–77.CrossRefGoogle Scholar
- 29.Spitzer AI, Richmond JC, Kraus VB, et al. Safety and efficacy of repeat administration of triamcinolone acetonide extended-release in osteoarthritis of the knee: a phase 3b, open-label study. Rheumatol Ther. 2019. https://doi.org/10.1007/s40744-019-0140-z.
- 30.US Center for Drug Evaluation and Research. Summary review (Zilretta). 2018. https://www.accessdata.fda.gov/. Accessed 22 Feb 2019.
- 32.American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edn. 2013. https://www.aaos.org/. Accessed 22 Feb 2019.
- 38.Bristol-Myers Squibb. KENALOG-40 injection (triamcinolone acetonide injectable suspension): US prescribing information. 2018. https://www.bms.com/. Accessed 22 Feb 2019.